EFG Asset Management North America Corp. lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,377 shares of the company’s stock after selling 1,955 shares during the quarter. EFG […]
HC Wainwright restated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) in a report released on Thursday, Benzinga reports. They currently have a $87.00 price objective on the stock. Several other brokerages also recently commented on APLS. Robert W. Baird boosted their target price on Apellis Pharmaceuticals from $90.00 to $105.00 […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its price target hoisted by The Goldman Sachs Group from $124.00 to $141.00 in a report released on Friday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages also recently commented on APLS. Wedbush lifted their target price on Apellis Pharmaceuticals from […]
Should You Buy or Sell Apellis Pharmaceuticals Stock? Get The Latest APLS Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, seven have assigned a buy recommendation and one has issued […]